SWOG clinical trial number
SLA01
CHARACTERIZATION OF THE EXPRESSION OF IMMUNE CHECKPOINTS IN GASTRIC CANCER FROM LATIN AMERICAN COUNTRIES
Open
Phase
Accrual
0%
Abbreviated Title
IMMUNE CHECKPOINTS IN GASTRIC CANCER FROM LATIN AMERICAN COUNTRIES
Participants
Instituto Nacional de Cancerologia (INCan), Mexico
Research committees
Gastrointestinal Cancer
Eligibility Criteria Expand/Collapse
a. Gastric carcinoma diagnosis and surgical resection
b. Patient must have 2 years minimum of follow-up after surgery or have died within two years after surgery.
c. Patients must have previously submitted their tissue for specimen banking at their local institution AND must have previously consented to their samples being used in future research.
d. Specimen requirements:
i. FFPE malignant primary tumor tissue from surgical resection, prior to chemotherapy, obtained within the last 5 years.
ii. The paraffin block or blocks sent should have enough tumor tissue to take at least three cores of tissue each three millimeters in diameter.
iii. At least one paraffin tumor block should remain at the institution enrolling the patient.
b. Patient must have 2 years minimum of follow-up after surgery or have died within two years after surgery.
c. Patients must have previously submitted their tissue for specimen banking at their local institution AND must have previously consented to their samples being used in future research.
d. Specimen requirements:
i. FFPE malignant primary tumor tissue from surgical resection, prior to chemotherapy, obtained within the last 5 years.
ii. The paraffin block or blocks sent should have enough tumor tissue to take at least three cores of tissue each three millimeters in diameter.
iii. At least one paraffin tumor block should remain at the institution enrolling the patient.
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/A022101
A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
SWOG Clinical Trial Number
S2107
Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
73%
Open
Phase
SWOG Clinical Trial Number
S2104
A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Research Committee(s)
Gastrointestinal Cancer
Activated
10/14/2021
Accrual
27%
Open
Phase